Dilemmas in treating smoldering multiple myeloma Review uri icon


MeSH Major

  • Antineoplastic Agents
  • Multiple Myeloma
  • Tumor Microenvironment


  • Novel therapies hold promise for high-risk smoldering multiple myeloma (SMM). Recent studies suggest that modern combination approaches can be options for high-risk SMM to obtain deep molecular responses with favorable toxicity profiles. Although pioneering treatment trials based on small numbers of patients suggest progression-free and overall survival benefits, application of the data to real-life practice remains to be validated. Therapeutic modulation of disease tempo, disease burden, clonal evolution, and tumor microenvironment in SMM remains to be understood and calls for reliable biomarkers reflective of disease biology. Here, we review studies that open a new management platform for SMM, address ongoing dilemmas in practice and under investigation, and highlight emerging scientific questions in the era of SMM treatment.

publication date

  • January 2015



  • Review



  • eng

PubMed Central ID

  • PMC4268248

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.56.4351

PubMed ID

  • 25422486

Additional Document Info

start page

  • 115

end page

  • 23


  • 33


  • 1